BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, Massari M, Foschi FG, Bernabucci V, Serio I, Prati GM, Negri E, Badia L, Caraceni P, Muratori P, Vitale G, Porro A, Morotti M, Mazzella G, Andreone P. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24:454-463. [PMID: 27976461 DOI: 10.1111/jvh.12663] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70. [PMID: 30245788 DOI: 10.1136/flgastro-2018-101017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
2 Parmar P, Shafran SD, Borgia SM, Doucette K, Cooper CL. Hepatitis C direct-acting antiviral outcomes in patients 75 years and older. JGH Open 2021;5:253-7. [PMID: 33553664 DOI: 10.1002/jgh3.12480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Mohammed Abdul MK, Snyder HS, Chunduru M, Lee SMK, Satapathy SK. Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure. Curr Treat Options Infect Dis 2020;:1-14. [PMID: 32837340 DOI: 10.1007/s40506-020-00231-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017;96:e9271. [PMID: 29390377 DOI: 10.1097/MD.0000000000009271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
5 Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jun MJ, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH; Real-World Evidence from the Asia Liver Consortium Investigators. Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clin Infect Dis 2020;71:2840-8. [PMID: 31777940 DOI: 10.1093/cid/ciz1160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
6 Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging 2018;35:843-57. [PMID: 30084012 DOI: 10.1007/s40266-018-0572-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Juanbeltz R, Goñi Esarte S, Úriz-Otano JI, Martínez Echeverría A, Elizalde I, Zozaya JM, Castilla J, San Miguel R. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med 2017;129:476-83. [PMID: 28343408 DOI: 10.1080/00325481.2017.1311197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
8 Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, Zadeikis N, Mensa FJ. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019;14:e0208506. [PMID: 30601818 DOI: 10.1371/journal.pone.0208506] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
9 Gitto S, Vizzutti F, Schepis F, Turco L, Aspite S, Vitale G, Arena U, Villa E, Laffi G, Debernardi-Venon W, Fanelli F, Andreone P, Marra F; DAA-TIPS group. Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. Dig Liver Dis 2019;51:870-4. [PMID: 30824409 DOI: 10.1016/j.dld.2018.11.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Pan CQ, Gayam V, Rabinovich C, Normatov M, Fidman B, Wang D, Garlapati P. Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States. J Am Geriatr Soc 2020;68:379-87. [PMID: 31647119 DOI: 10.1111/jgs.16206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Amoros-Reboredo P, Soy D, Hernandez-Hernandez M, Lens S, Mestres C. Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Int J Environ Res Public Health 2020;17:E3776. [PMID: 32466526 DOI: 10.3390/ijerph17113776] [Reference Citation Analysis]
13 Villani R, Monami M, Di Cosimo F, Fioravanti G, Mannucci E, Vendemiale G, Serviddio G. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. J Viral Hepat 2019;26:1249-56. [PMID: 31243849 DOI: 10.1111/jvh.13169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
14 Miotto N, Mendes LC, Zanaga LP, Lazarini MSK, Goncales ESL, Pedro MN, Goncales FL Jr, Stucchi RSB, Vigani AG. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13:e0199941. [PMID: 29990371 DOI: 10.1371/journal.pone.0199941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
15 Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85. [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
16 Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open 2019;9:e029066. [PMID: 31383704 DOI: 10.1136/bmjopen-2019-029066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
18 Huynh T, Hu KQ. Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. Dig Dis Sci 2021;66:1327-34. [PMID: 32405981 DOI: 10.1007/s10620-020-06286-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Hiraoka A, Michitaka K, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Miyata H, Tsubouchi E, Kishida M, Hirooka M, Abe M, Matsuura B, Ninomiya T, Hiasa Y. Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2-year observation period. Hepatol Res 2018;48:502-8. [PMID: 29314571 DOI: 10.1111/hepr.13051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Fabrizio C, Saracino A, Scudeller L, Milano E, Dell'Acqua R, Bruno G, Lo Caputo S, Monno L, Milella M, Angarano G. The elderly and direct antiviral agents: Constraint or challenge? Dig Liver Dis. 2017;49:1036-1042. [PMID: 28651903 DOI: 10.1016/j.dld.2017.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 De Santis A, Maggi D, Lubrano Lobianco F. Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people. Aging Medicine 2021;4:304-16. [DOI: 10.1002/agm2.12190] [Reference Citation Analysis]
22 Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection 2018;46:607-15. [PMID: 29808463 DOI: 10.1007/s15010-018-1157-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
23 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
24 Kinoshita A, Koike K, Mizuno Y, Ogata I, Kobayashi Y, Hasegawa K, Shiraishi K, Yoshida H, Nakata R, Yamada N, Yasuda K. Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years. Geriatr Gerontol Int 2020;20:578-83. [PMID: 32267087 DOI: 10.1111/ggi.13919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
26 Pariente A, Arpurt JP, Remy AJ, Rosa-Hezode I, Causse X, Heluwaert F, Macaigne G, Henrion J, Renou C, Schnee M, Salloum H, Hommel S, Pilette C, Arotcarena R, Barjonet G, Lison H, Bourhis F, Jouannaud V, Pauwels A, Le-Bricquir Y, Geagea E, Condat B, Ripault MP, Zanditenas D, de Montigny-Lenhardt S, Labadie H, Tissot B, Maringe E, Cadranel JF, Hagege H, Lesgourgues B; Association Nationale des Gastroenterologues des Hopitaux (ANGH). Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals. Ann Hepatol 2019;18:193-202. [PMID: 31113590 DOI: 10.5604/01.3001.0012.7912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017;46:711-721. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
28 Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. J Hepatol. 2017;. [PMID: 29223371 DOI: 10.1016/j.jhep.2017.11.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
29 Hiraoka A, Kitahata S, Izumoto H, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Hirooka M, Tokumoto Y, Abe M, Matsuura B, Hiasa Y, Michitaka K. Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension. Hepatol Res 2018;48:E354-9. [PMID: 28940597 DOI: 10.1111/hepr.12984] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
30 Pugliese N, Giorgini A, Maggi D, Capogreco A, Dibenedetto C, Lubrano Lobianco F, Dal Buono A, Monico S, Meli R, Battezzati PM, Lleo A, De Santis A, Zuin M, Aghemo A. Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. Expert Opin Drug Saf 2021;20:839-43. [PMID: 33881366 DOI: 10.1080/14740338.2021.1921144] [Reference Citation Analysis]
31 Amoros-Reboredo P, Sotoca JM, Mariño Z, Rodríguez-Tajes S, Pocurull A, Soy D, Forns X, Lens S. Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. Eur J Gastroenterol Hepatol 2020;32:389-94. [PMID: 31441796 DOI: 10.1097/MEG.0000000000001518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Flamm S, Peng CY, Shibolet O, Nahass R, Hwang P, Barr E, Robertson MN, Haber BA. Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older. Gerontol Geriatr Med 2019;5:2333721418817398. [PMID: 30891470 DOI: 10.1177/2333721418817398] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Mikulic D, Mrzljak A. Liver transplantation and aging. World J Transplant 2020; 10(9): 256-266 [PMID: 32995320 DOI: 10.5500/wjt.v10.i9.256] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
35 El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, Ezzat S, Tahoon M, Abdelsalam L, Abdelhakam SM, Ali-Eldin Z. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med 2019;10:295-302. [PMID: 34652758 DOI: 10.1007/s41999-019-00167-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Qureshi K, Petersen T, Andres J. Hepatitis C Treatment Differences in Elderly Patients: Single-Center Retrospective Study. Ann Pharmacother 2020;54:113-21. [PMID: 31452381 DOI: 10.1177/1060028019871352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]